Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Louisville, Kentucky Clinical Trials

A listing of Louisville, Kentucky clinical trials actively recruiting patient volunteers.

RESULTS

Found (36) clinical trials

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged 3 months.

Phase

5.74 miles

Learn More »

A Study of Obinutuzumab Rituximab Polatuzumab Vedotin and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory FL, and with rituximab, polatuzumab vedotin, and venetoclax in participants with DLBCL. Participants with FL who achieve complete response (CR), partial response (PR), or stable disease ...

Phase

5.74 miles

Learn More »

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Screening assessments will occur within 48 hours of study drug administration (Day 1). Baseline assessments will be performed following eligibility verification based on screening assessments. Participants will be monitored for safety 24 hours post study drug infusion. The site will contact the participant and/or parent (or appropriate legal representative) via ...

Phase

5.74 miles

Learn More »

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

The study will be conducted in two segments. The first segment of the study, designated Phase 1a, will be a dose escalation design in order to assess the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of ascending doses of AZD4635 as monotherapy, in combination with durvalumab or durvalumab plus ...

Phase

5.74 miles

Learn More »

A Study of LY3200882 in Participants With Solid Tumors

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Phase

5.74 miles

Learn More »

Atezolizumab Pemetrexed Disodium Cisplatin and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

PRIMARY OBJECTIVES: I. To evaluate if the regimen of neoadjuvant cisplatin-pemetrexed disodium (pemetrexed)-atezolizumab, surgery +/- radiation, then maintenance atezolizumab is feasible and safe for patients with resectable malignant pleural mesothelioma. SECONDARY OBJECTIVES: I. To evaluate progression free survival (both by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 and also ...

Phase

5.74 miles

Learn More »

Open-Label Dose-Finding Pharmacokinetics Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

This is a Phase 1, multicenter, open-label, PK, safety and tolerability study of oritavancin in pediatric patients (<18 years of age) with suspected or diagnosed Gram-positive bacterial infections or pediatric patients requiring peri-operative prophylactic antibiotics. Approximately 52 patients will be enrolled at 5-10 US centers. This study will include 5 ...

Phase

5.74 miles

Learn More »

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy

Phase

5.74 miles

Learn More »

AMG 404 in Patients With Advanced Solid Tumors.

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.

Phase

5.74 miles

Learn More »

A Study of ASP1948 Targeting an Immune Modulatory Receptor in Subjects With Advanced Solid Tumors

This is a dose-escalation and expansion study of ASP1948 as a single agent and in combination with nivolumab. The study consists of 3 periods for monotherapy and combination therapy: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify. The escalation cohorts will evaluate escalating ...

Phase

5.74 miles

Learn More »